Rezolute, Inc. is a late-stage rare disease biopharmaceutical company focused on developing therapies for refractory and debilitating hypoglycemia associated with hyperinsulinism (HI). Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody targeting the insulin receptor to restore normalized glucose levels. The company is developing ersodetug for congenital HI and other forms of hyperinsulinism, with a Phase 3 study (sunRIZE) completed and ongoing FDA discussions regarding potential marketing application.
expected 2026-12-24
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-09-24 | 2026-06-30 | 0001104659-26-110420 | EDGAR | 54K words |
| 2025-09-17 | 2025-06-30 | 0001104659-25-090848 | EDGAR | 42K words |
| 2024-09-19 | 2024-06-30 | 0001558370-24-012901 | EDGAR | 44K words |
| 2023-09-14 | 2023-06-30 | 0001558370-23-015755 | EDGAR | 53K words |
| 2022-09-15 | 2022-06-30 | 0001558370-22-014432 | EDGAR | 53K words |
| 2021-09-15 | 2021-06-30 | 0001104659-21-115980 | EDGAR | 54K words |
| 2020-10-13 | 2020-06-30 | 0001104659-20-114497 | EDGAR | 53K words |
| 2019-09-10 | 2019-06-30 | 0001144204-19-043983 | EDGAR | 54K words |
| 2018-10-15 | 2018-06-30 | 0001144204-18-053849 | EDGAR | 38K words |
| 2017-09-22 | 2017-06-30 | 0001144204-17-049237 | EDGAR | 37K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-05 | 2026-09-30 | 0001104659-26-123364 | EDGAR | 19K words |
| 2026-02-12 | 2025-12-31 | 0001104659-26-014334 | EDGAR | 23K words |
| 2025-11-06 | 2025-09-30 | 0001104659-25-107781 | EDGAR | 19K words |
| 2025-05-13 | 2025-03-31 | 0001558370-25-007582 | EDGAR | 24K words |
| 2025-02-12 | 2024-12-31 | 0001558370-25-000867 | EDGAR | 22K words |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014893 | EDGAR | 19K words |
| 2024-05-15 | 2024-03-31 | 0001558370-24-008294 | EDGAR | 24K words |
| 2024-02-13 | 2023-12-31 | 0001558370-24-001069 | EDGAR | 21K words |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018839 | EDGAR | 16K words |
| 2023-05-11 | 2023-03-31 | 0001558370-23-009405 | EDGAR | 22K words |
| 2023-02-10 | 2022-12-31 | 0001558370-23-001120 | EDGAR | 19K words |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017176 | EDGAR | 17K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-16 | 0001104659-26-127490 | EDGAR | — |
| 2026-11-13 | 0001104659-26-126502 | EDGAR | 1K words |
| 2026-11-05 | 0001104659-26-123336 | EDGAR | 2K words |
| 2026-10-29 | 0001104659-26-120205 | EDGAR | 4K words |
| 2026-10-14 | 0001104659-26-115874 | EDGAR | 1K words |
| 2026-10-05 | 0001104659-26-113503 | EDGAR | 1K words |
| 2026-09-24 | 0001104659-26-110412 | EDGAR | 2K words |
| 2026-03-24 | 0001104659-26-033592 | EDGAR | 1K words |
| 2026-02-12 | 0001104659-26-014287 | EDGAR | 2K words |
| 2026-01-07 | 0001104659-26-001556 | EDGAR | 4K words |
302 total filings indexed. 270 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001509261 |
| Ticker | RZLT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.rezolutebio.com |
| Listed | 2011-12-23 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/RZLT (~200 tokens, structured JSON with cryptographic provenance)